Cancer Center Administration undertakes a range of activities essential to maximizing the effectiveness of CCSG-supported infrastructure and adding value to the UC Davis cancer research enterprise and the integrated cancer program with the Lawrence Livermore National Laboratory (LLNL). Administration oversight of CCSG expenditures ensures that they are used only in the ways specified by NCI Guidelines and the proposal for competitive renewal of NCI designation. Activities encompass support for scientific programs and collaborations, membership, shared resources, developmental funds used for pilot studies, recruitment and developing shared resources, clinical trial data management, and leadership organizations. The Administration adds value to the cancer research effort by planning and organizing """"""""Cross Talk"""""""" meetings, cancer biology seminars, an annual research symposium, and various collaborative conferences targeting Initiatives In breast cancer, Inflammation, stem cells, Imaging, brain tumors, and key research communities at UC Davis and LLNL. In addition, Administration is responsible for the coordination of Cancer Center membership, the Cancer Center Web site (http://cancer.ucdmc.ucdavis.edu), and various list serves and communication tools. Central operations, fiscal affairs, contract and grant administration, purchasing, event planning, proposal development, and public affairs are other core services provided by Cancer Center Administration to the Director, senior leaders and to the membership at large to advance strategic plans, new areas of research, and team science.
Administration maintains the research organization and data about the research organization, provides staff expertise in financial management, grant proposal development scientific meeting development internal and external relations of significance to the research enterprise, and modern forms of electronic communication such as list servers and the Internet. In these ways. It builds the scope of cancer research at UCD.
|Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591|
|Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543|
|Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32|
|Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67|
|York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :|
|Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283|
|(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88|
|Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136|
|Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808|
|Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755|
Showing the most recent 10 out of 733 publications